RecruitingPhase 3NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Studying Paraneoplastic cerebellar degeneration
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-08046054(drug)
- Enrollment
- 680 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2032
Study locations (30)
- Alabama Oncology, Alabaster, Alabama, United States
- Alabama Oncology, Bessemer, Alabama, United States
- Alabama Oncology, Bruno Cancer Center, Birmingham, Alabama, United States
- Alabama Oncology, Birmingham, Alabama, United States
- Southern Cancer Center, Daphne, Alabama, United States
- Southern Cancer Center, PC, Foley, Alabama, United States
- Alaska Oncology and Hematology, Anchorage, Alaska, United States
- Highlands Oncology Group, PA, Fayetteville, Arkansas, United States
- Highlands Oncology Group, PA, Rogers, Arkansas, United States
- Highlands Oncology Group, PA, Springdale, Arkansas, United States
- Highlands Oncology Group, Springdale, Arkansas, United States
- Providence Medical Foundation, Fullerton, California, United States
- Providence St. Jude Medical Center, Fullerton, California, United States
- Rocky Mountain Cancer Centers,LLP, Denver, Colorado, United States
- Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07144280 on ClinicalTrials.govOther trials for Paraneoplastic cerebellar degeneration
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06965166Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal CancerMayo Clinic
- ACTIVE NOT RECRUITINGPHASE2NCT05557591A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)Regeneron Pharmaceuticals
- RECRUITINGNANCT06080841Curcumin Supplementation in Cervical CancerNational Institute of Cancerología
- ACTIVE NOT RECRUITINGPHASE1NCT05338775A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC